

**Table S2: Summary of selected unclassified patients<sup>a</sup>**

Patient code	IHE-PF	IHE-HHQ	UCP-PF		UCP-HHQ		no. of pos. samples	host <sup>d</sup>	Am <sup>e</sup>
	1x <sup>b</sup>	1x <sup>b</sup>	1x <sup>b</sup>	2x <sup>c</sup>	1x <sup>b</sup>	2x <sup>c</sup>			
M068 (n=6)			1	1		1	3	n	
M074 (n=8)				1		1	2	n	P, V, A
M077 (n=8)	1	1					2	n	P
T155 (n=9)	1	2			1		4	n, a, t	P
T161 (n=11)	1		2				3	a, t	M
T167 (n=12)		1	1				2	n, a, t	
V080 (n=8)		1	1		1	1	3	n	V, P
V093 (n=20)		1	1		2		4	n, a, t	M, V
T160 (n=15)					2		2	a	P

<sup>a</sup> Unclassified patients with more than one positive PCR method result; the number of positive PCR replicas are indicated below each method

<sup>b</sup> No. of single-positive PCR triplicates

<sup>c</sup> No. of double-positive PCR triplicates

<sup>d</sup> Host risk factors for IA: a, allogeneic stem cell transplantation; n, neutropenia; t, T-cell-suppressive therapy

<sup>e</sup> *Aspergillus* active antimycotic therapy. A, ambisome; M, micafungin; P, posaconazole; V, voriconazole.